Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.08

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	5/7/2002 8:29:40 AM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

08:25 ET Time to bottom-fish in biotech-- Solly Salomon Smith Barney believes that this is an opportune period to accumulate positions selectively in key large-cap biotech stocks; large cap biotech co's are trading at a forward PEG ratio which is currently below the PEG for the DRG index and nearly on par for the S&P 500; believes that at most there is additional downside of 5-15% on the BTK index; upcoming catalysts include: ASCO newsflow, BGEN's Amevive FDA panel meeting, DNA's Avastin Phase III data, and AMGN's Aranesp and Neulasta market launches. Recommends AMGN, IDPH, DNA, and GENZ.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next